サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ジプラシドンの世界市場-2022-2029
市場調査レポート
商品コード
1129251

ジプラシドンの世界市場-2022-2029

Global Ziprasidone Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ジプラシドンの世界市場-2022-2029
出版日: 2022年09月29日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

精神疾患の世界の蔓延が市場成長の原動力となることが予想されます。

世界保健機関（WHO）によると、統合失調症は精神病を引き起こし、かなりの障害を伴い、個人、家族、社会、教育、職業機能など、生活のあらゆる分野に影響を及ぼす可能性があるとされています。統合失調症は、全世界で約2,400万人、300人に1人（0.32%）の割合で発症していると言われています。成人では222人に1人（0.45%）です。他の多くの精神疾患と比較すると、それほど広く普及しているわけではありません。そのため、特定の精神疾患の増加により薬の需要が高まっており、ジプラシドンによる治療が主に行われています。

さらに、この薬は服用することで目に見える即効性があり、すぐに症状が緩和されるため推奨されています。さらに、Dr. Reddy'sは、2020年3月17日にジプラシドン・メシル酸塩の発売を発表し、薬局に価値を与えることで、医療をより安価に提供することを意図しています。したがって、上記の記述から、予測期間において市場を牽引することが期待されます。

ジプラシドンに関連する副作用が市場成長の妨げになると予想されます。

ジプラシドンは、体重増加、糖尿病、高コレステロールのリスクを高める薬です。また、患者に心拍障害、QT延長症候群、制御不能な心不全の既往がある場合、ジプラシドンの使用は推奨されず、製品の需要を低下させます。ジプラシドンの需要が少ないのは、呼吸器感染症、錐体外路症状、アカシジア、視力低下、めまい、嘔吐、頭痛、吐き気などの副作用があるためです。同様に、ハロペリドール、クエチアピン、アリピプラゾールといったより効果的な代替薬が入手可能であることも、ジプラシドンの市場需要を減少させます。また、本製品を使用することによるメタボリックシンドロームの健康被害は、予測期間中の市場成長を阻害するものと思われます。

産業分析

ジプラシドン市場は、サプライチェーン分析、価格分析など、様々な産業要因に基づいた市場の詳細な分析を提供します。

COVID-19の影響分析

COVID-19のパンデミックはヘルスケアシステムと市場に中程度の影響を及ぼしています。COVID-19は人々の精神的健康や生活の質に影響を与えます。COVID-19は、特に患者や医療従事者にパニック、不安、抑うつ、不眠を誘発します。COVID-19の患者さんには精神薬が処方されることがあります。また、COVID-19の患者さんの中には、様々な理由で精神科の薬を使用している方もいます。そのため、精神科治療薬とCOVID-19の治療に使用される薬剤との間で薬物-薬物相互作用（DDI）が起こる危険性があります。チトクロームP450系は、いくつかの精神科治療薬の代謝を担っています。

一方、パンデミックは、サプライチェーンとプロセスを中断させます。多くの企業は、製品の入手可能性を確保し、サプライチェーンを保護するために、他の地域へと変化していくでしょう。したがって、上記の文から、市場は影響を受け、それは経済活動の再開と迅速にトラクションを得ることが期待されるようになっています。

世界のジプラシドン市場レポートでは、約45+市場データ表、40+図、180pagesへのアクセスを提供することになります。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

  • 市場インパクトファクター
    • 促進要因
      • 精神疾患の世界の蔓延が市場成長の原動力になると予想されます。
    • 抑制要因
      • ジプラシドンに伴う副作用が市場成長を阻害すると予想されます。
    • 市場機会
    • 影響分析

第5章 産業分析

  • サプライチェーン分析
  • 価格設定分析
  • アンメットニーズ分析
  • パイプライン分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 投与経路別

  • 経口カプセル
  • 筋肉内注射
  • その他

第8章 用途別

  • 統合失調症
  • 双極性躁病
  • アジテーション
  • その他

第9章 販売チャネル別

  • 病院内薬局
  • オンライン薬局
  • 小売店
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第12章 企業プロファイル

  • Pfizer Inc
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Sandoz AG
  • Lupin Pharmaceuticals, Inc.
  • Mylan Pharmaceuticals
  • Apotex
  • Dr. Reddy's laboratories Ltd.
  • Wockhardt
  • Aurobindo Pharma USA

第13章 ジプラシドンの世界市場-DataM

目次
Product Code: DMPH5804

Market Overview

The Ziprasidone Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Ziprasidone, commonly known as Geodon, is an atypical antipsychotic of the second generation that is used to treat schizophrenia and bipolar disorder, among other things. The pills include hydrochloride salt and ziprasidone hydrochloride, which rebalances dopamine and serotonin in the brain to improve mood and behavior.

Market Dynamics

The increasing prevalence of mental disorders worldwide is expected to drive market growth.

According to the World Health Organization, Schizophrenia causes psychosis, is associated with considerable disability and may affect all areas of life, including personal, family, social, educational, and occupational functioning. Schizophrenia affects around 24 million people globally or one in every 300 people (0.32 percent). Adults have a rate of 1 in 222 (0.45 percent). It is not as widespread as many other mental illnesses. Therefore, the demand for the medication has increased due to an increase in certain mental health conditions, which are largely treated with Ziprasidone.

Furthermore, the medicine is recommended because of the immediate effect visible when delivering the dose, resulting in immediate alleviation. Moreover, Dr. Reddy's announced the launch of Ziprasidone Mesylate on March 17, 2020, intending to make healthcare more affordable by giving value to the pharmacy. Thus, from the above statements, the market is expected to drive in the forecast period.

Side effects associated with ziprasidone are expected to hamper the market growth.

Ziprasidone is a medicine that increases the risk of weight gain, diabetes, and high cholesterol. Also, using ziprasidone is not recommended if the patient has a history of heart rhythm disorders, long QT syndrome, or uncontrolled heart failure, which diminishes the product's demand. Ziprasidone's low demand is due to side effects such as respiratory tract infections, extrapyramidal symptoms, akathisia, altered eyesight, dizziness, vomiting, headache, and nausea. Likewise, the availability of more effective alternatives like haloperidol, quetiapine, and aripiprazole diminishes market demand for ziprasidone. The metabolic syndrome health hazards associated with utilizing the product will hamper the market growth in the forecast period.

Industry Analysis

The ziprasidone market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. COVID-19 has an impact on people's mental health and quality of life. COVID-19 induces panic, anxiety, depression, and insomnia, particularly in patients and health care workers. Patients with COVID-19 may be prescribed mental medications. In addition, some COVID-19 patients have been using psychiatric medicines for various reasons. As a result, there is a risk of drug-drug interaction (DDI) between psychiatric medicines and drugs used to treat COVID-19. The cytochrome P450 system is responsible for the metabolism of several psychiatric medications.

In contrast, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

Oral Capsules segment is expected to hold the largest market share in ziprasidone market

The oral capsules segment is expected to dominate in 2021. The segment benefits because the capsules have been approved by the US Food and Drug Administration (FDA) for long-term treatment of individuals with bipolar disorder due to their effectiveness and patient tolerability. The simplicity of long-term usage required due to the chronic nature of the sickness and the requirement of lesser doses of the medicine to be given at different times to improve the efficacy of the treatment also contribute to the demand. Oral capsules are less likely to cause an overdose. Oral capsules for Ziprasidone are less expensive than injections, making the medication more accessible and increasing demand. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global ziprasidone market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of bipolar disorders, high adoption of ziprasidone drugs, product launches and acquisitions by the market key players and rising clinical trials in the region are some factors the market is expected to boost in the forecast period. For instance, according to the National Institute of Mental Health, Bipolar disorder affects approximately 5.7 million adult Americans, or about 2.6% of the U.S. age 18 and older every year. Moreover, bipolar illness affects an equal number of men and women and affects people of all ages, races, ethnic groups, and social classes. Additionally, Upjohn, a part of Pfizer, announced the completion of the Phase 3 pediatric clinical trial for Geodon on November 10, 2020. (ziprasidone). The study looked at the efficacy and safety of ziprasidone in children and adolescents with bipolar I disorder. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the ziprasidone market are Pfizer Inc., Sandoz AG, Lupin Pharmaceuticals, Inc., Mylan Pharmaceuticals, Apotex, Dr. Reddy's laboratories Ltd. , Wockhardt, Aurobindo Pharma USA.

Pfizer Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. It has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

Product Portfolio:

GEODON (ziprasidone HCl): GEODON Capsules are indicated for treating schizophrenia in adults, acute treatment in adults as monotherapy of manic or mixed episodes associated with bipolar I disorder, and maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults.

The global ziprasidone market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing prevalence of mental disorders worldwide is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with ziprasidone are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs
  • 5.4. Pipeline Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Route of Administration

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 7.2. Oral Capsules*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Intramuscular Injection
  • 7.4. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. Schizophrenia*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Bipolar Mania
  • 8.4. Agitation
  • 8.5. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Pfizer Inc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Sandoz AG
  • 12.3. Lupin Pharmaceuticals, Inc.
  • 12.4. Mylan Pharmaceuticals
  • 12.5. Apotex
  • 12.6. Dr. Reddy's laboratories Ltd.
  • 12.7. Wockhardt
  • 12.8. Aurobindo Pharma USA

LIST NOT EXHAUSTIVE

13. Global Ziprasidone Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us